Euclidean Capital LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Euclidean Capital LLC reported 10 stock positions worth $266.1 million. Its top holding was iShares MSCI India ETF (INDA) at 46.9% of the portfolio, followed by Vanguard Ftse All-World Ex-U (VEU, 45.4%) and Foghorn Therapeutics (FHTX, 2.2%). Compared with Q4 2024, it added to 1 and reduced 1. The biggest buy was Vanguard Ftse All-World Ex-U (VEU, shares +97%) and the biggest sale SS SPDR S&P 500 ETF Trust-US (SPY, shares −100%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001825034
- Portfolio Value
- $266.1M (Q1 2025)
- SEC Filing
- 0001012975-25-000241 ↗ filed May 15, 2025
Holdings Value
Holdings 10 stocks · $266.1M
| INDA iShares MSCI India ETF | 46.91% | 2,425,144 | $124.8M | No change |
| VEU Vanguard Ftse All-World Ex-U | 45.40% | 1,991,884 | $120.8M | Add +96.5% |
| FHTX Foghorn Therapeutics Inc. | 2.16% | 1,573,761 | $5.7M | No change |
| ORIC Oric Pharmaceuticals Inc. | 2.07% | 989,410 | $5.5M | No change |
| PMVP PMV Pharmaceuticals Inc. | 1.08% | 2,627,643 | $2.9M | No change |
| SPY SS SPDR S&P 500 ETF Trust-US | 0.86% | 4,104 | $2.3M | Reduce -99.5% |
| ALEC Alector Inc. | 0.60% | 1,307,858 | $1.6M | No change |
| SRZN Surrozen Inc. | 0.38% | 87,696 | $1.0M | No change |
| RAPT THERAPEUTICS INC | 0.30% | 657,899 | $803K | No change |
| TNYA Tenaya Therapeutics Inc. | 0.22% | 1,015,705 | $579K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $5K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| SRZNW Surrozen Inc.-CW25 | *W EXP 08/01/203 | 170,833 | $5K | No change |
Total filed on the 13F, all lines: $266.1M.
Portfolio Sells Q4 2024 → Q1 2025
| SPY SS SPDR S&P 500 ETF Trust-US | Reduce -99.5% | 0.86% | −70.44 |
Portfolio Buys Q4 2024 → Q1 2025
| VEU Vanguard Ftse All-World Ex-U | Add +96.5% | 45.40% | +37.51 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 10 | $439.8M | VEU, VTV, INDA, ORIC, TMS |
| Q1 2026 | 9 | $392.3M | VEU, VTV, INDA, ORIC, FHTX |
| Q4 2025 | 11 | $369.4M | VEU, VTV, INDA, FHTX, ORIC |
| Q3 2025 | 10 | $238.0M | VEU, INDA, ORIC, FHTX, ALEC |
| Q2 2025 | 10 | $305.7M | VEU, INDA, ORIC, FHTX, PMVP |
| Q1 2025 | 10 | $266.1M | INDA, VEU, FHTX, ORIC, PMVP |
| Q4 2024 | 10 | $736.7M | SPY, INDA, VEU, ORIC, FHTX |
| Q3 2024 | 11 | $906.8M | SPY, INDA, VEU, FHTX, ORIC |
| Q2 2024 | 10 | $795.8M | SPY, INDA, FHTX, ORIC, ALEC |
| Q1 2024 | 12 | $780.0M | SPY, INDA, GLD, ORIC, FHTX |